Premium
Clinico‐pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience
Author(s) -
Fonseca de Jesus Victor Hugo,
Guedes Camandaroba Marcos Pedro,
Spina Donadio Mauro Daniel,
Cabral Audrey,
Pimentel Muniz Thiago,
Moura Leite Luciana,
Ferreira Sant’Ana Lucas,
Luiz da Costa Wilson,
Curado Maria Paula,
Coimbra Felipe José Fernandez
Publication year - 2019
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25312
Subject(s) - medicine , pancreatic cancer , cancer , pathological , disease , population , diabetes mellitus , gastroenterology , pancreatic disease , pancreas , family history , oncology , environmental health , endocrinology
Background Pancreatic cancer plays an important role in cancer‐related mortality. Few studies have been performed in Brazil to characterize patients affected by this disease. We aimed to describe the clinico‐pathological characteristics and the survival of patients with pancreatic cancer seen at AC Camargo Cancer Center (ACCCC). Methods We included patients ≥ 18‐year old, with a histologically confirmed diagnosis of exocrine pancreatic cancer, that attended at least one visit at ACCCC from 2008 to 2016. Results The study included 739 patients. Median age at diagnosis was 64 years. Most patients were male. About 5% presented a family history of pancreatic cancer. A total of 40% had diabetes and 51.4% presented with ECOG performance status 1. Tumors most often arose in the pancreatic head and roughly half of the patients had metastatic disease at presentation. Median overall survival of patients with potentially resectable disease submitted to surgery at ACCCC was 35.4 months. Median overall survival times of patients with the unresectable and metastatic disease were 14.1 and 9.3 months, respectively. Conclusions The features of our population match those of studies done in developed countries. We believe multicentric data from patients with pancreatic cancer in Brazil could enable more effective preventive and therapeutic approaches to the disease.